Screening, treatment, and follow-up. Of 41 screened and treated patients, 34 completed the induction and consolidation phase. Seven patients discontinued treatment according to described reasons. Of the 34 patients, final restaging was performed during cycle 14 until cycle 15, day 1. Twenty-two patients reached CR at final restaging and stopped treatment (1 patient stopped due to AE, arthralgia I°, but reaching CR at final restaging). Six patients continued ibrutinib in maintenance, 6 patients discontinued due to different described reasons. At time of data cut-off, 1 patient reached EOT.